20.08.2021 • News

Dow Hikes Louisiana Methyl Acrylate Capacity

Dow is investing an undisclosed sum in its methyl acrylate production to meet growing demand both in North America and worldwide. The project at its St Charles operations in Hahnville, Louisiana, USA, will add 50,000 t/y of capacity by the first half of 2022. Dow said the extra output will “enable global growth with a focus on supplying North American demand.”

“Methyl acrylate is a critical component of a wide range of applications where we are seeing a rise in market demand, from water treatment and thermoplastic products to inks, resins and packaging materials,” said Jim Knaub, global business director, Dow Performance Monomers & Plastics Additives.

Once the capacity increase is on stream, Dow said its St Charles operations will focus primarily on producing methyl acrylate and 2-ethyl-hexyl acrylate. Ethyl acrylate production will be fully supported by operations in Deer Park, Texas, which Dow said has capacity to manage existing customer demand.

Last month, Dow announced a series of global “incremental, high-return” capacity expansions to support fast-growing demand across key end-markets, while in June it revealed plans to build an integrated MDI distillation and pre-polymers facility in Freeport, Texas, to go on stream in 2023.

Author: Elaine Burridge, Freelance Journalist

Dow is investing an undisclosed sum in its methyl acrylate production to meet...
Dow is investing an undisclosed sum in its methyl acrylate production to meet growing demand both in North America and worldwide. The project at its St Charles operations in Hahnville, Louisiana, USA, will add 50,000 t/y of capacity, which is due online in first half 2022. (c) Dow

Company

Logo:

Dow Chemical Company

2211 HH Dow Way
48674 Midland, MI
US

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read